BiolineRx

A biopharmaceutical company focused on developing therapies in oncology and rare diseases.

Biotechnology
Public on TASE on Apr, 2007
Public on NASDAQ on Mar, 2014
Public Modi'in-Maccabim-Re'ut, Israel Founded 2003
Last updated 2026-09-06
Total raised
$1.6B
Last: Debt Financing 2024-04
Stage
Public
Founded
2003
Headcount
25
HQ
Modi'in-Maccabim-Re'ut, Israel
Sector
Biotechnology
Website ↗LinkedIn ↗Registrar ID: 513398750 (BioLineRx Ltd.)

About

BioLineRx is a publicly traded drug development company headquartered in Israel. It focuses on identifying, in-licensing, and developing therapeutic candidates, primarily in oncology and rare diseases. The company's main activities include the development and commercialization of innovative therapeutic solutions, leading promising compounds through preclinical and clinical trials, and partnering with other companies for further development and commercialization.

Funding history · 25 rounds · $1.6B total

29 events/rounds · $1.6B Total Funding: $41.0M in Private Equity, $411.7M in Public Equity, $1.2B in Debt
Aug 2026
Public Offering $3.8M EDGAR filing SEC-EDGAR 424B5
Apr 2025
Public Offering $4.9M EDGAR filing SEC-EDGAR 424B5
Jan 2025
Public Offering $10.0M EDGAR filing SEC-EDGAR 424B5
Apr 2024
Public Offering $6.0M EDGAR filing SEC-EDGAR 424B5
Sep 2022
Public Offering $15.0M EDGAR filing SEC-EDGAR 424B5
Sep 2021
Public Offering $25.0M EDGAR filing SEC-EDGAR 424B5
Jan 2021
Public Offering $30.0M EDGAR filing SEC-EDGAR 424B5
Jul 2020
Public Offering $13.4M EDGAR filing SEC-EDGAR 424B3
Feb 2019
Public Offering $15.4M EDGAR filing SEC-EDGAR 424B5
Oct 2017
Public Offering $30.0M EDGAR filing SEC-EDGAR 424B5
Jul 2017
Public Offering $9.6M EDGAR filing SEC-EDGAR 424B5
Apr 2017
Public Offering $25.0M EDGAR filing SEC-EDGAR 424B5
Apr 2015
Debt Financing $1.2B EDGAR filing SEC-EDGAR 8-K
Mar 2015
Public Offering $25.0M EDGAR filing SEC-EDGAR 424B5
Mar 2014
Public Offering $21.0M EDGAR filing SEC-EDGAR 424B5
Aug 2013
Public Offering $2.7M EDGAR filing SEC-EDGAR 424B3
May 2013
Public Offering $20.0M EDGAR filing SEC-EDGAR 424B5
Feb 2013
Public Offering $8.0M EDGAR filing SEC-EDGAR 424B5
Oct 2012
Public Offering $15.0M EDGAR filing SEC-EDGAR 424B3
Oct 2009
Grant $6.0M biolinerx.com ↗
★ BioLineRx★ Pan Atlantic Group (the Albert Friedberg Family)★ Canada-Israel Research & Development Foundation (CIIRDF)
Feb 2007
Follow-on PO $57.0M globes.co.il
★ Leader Capital Markets★ Clal Finance UnderwritingHadasitGiza Venture CapitalPitango Venture CapitalTeva Pharmaceutical Industries Ltd.
Sep 2005
A Round $9.0M tracxn.com
★ 2 more★ Pitango VC★ Giza Venture Capital★ one other undisclosed investor2 more investors
Dec 2004
Grant $6.0M biolinerx.com
★ BioLineRx★ Pan Atlantic Group (the Albert Friedberg Family)
Dec 2004
Grant $21.0M globes.co.il
2003
Seed $32.0M star-ventures.com
★ Teva★ Orbimed★ Yehuda Zisapel★ Hadasit Bio-Holdings★ Jerusalem Development Authority

Acquisitions · 1

Mar 2017
Agalimmune $6.0M

Headcount over time

25 employees (2026-09) · 1 point
25 25 2026-09

Offices

Modi'in-Maccabim-Re'ut, Israel · HQ / main office

Q&A

What was BioLineRx's most recent funding event?
In April 2025, BioLineRx completed a Public Offering, raising $4,870,000.
When did BioLineRx go public on the TASE and NASDAQ?
BioLineRx went public on the TASE in April 2007 and on NASDAQ in March 2014.
What was the amount of the Public Offering in March 2015 and its valuation?
In March 2015, BioLineRx had a Public Offering on NASDAQ with a valuation of $72,300,000. The amount raised was not specified in the public offerings data.
What is BioLineRx's primary focus in drug development?
BioLineRx is a biopharmaceutical company focused on developing therapies primarily in oncology and rare diseases.
What was the amount of the Public Offering in April 2017 and its valuation?
In April 2017, BioLineRx had a Public Offering on NASDAQ, raising $25,000,000 with a valuation of $69,000,000.
What is the employee count range for BioLineRx?
BioLineRx has an employee count in the 11-50 range.
When did BioLineRx acquire Agalimmune and for what amount?
BioLineRx acquired Agalimmune in March 2017 for $6,000,000.
What is the total amount of funding BioLineRx has raised to date?
BioLineRx has raised a total of $120,000,000 USD.
What was the most recent debt financing round for BioLineRx?
The most recent debt financing round for BioLineRx was in April 2024, raising $20,000,000.

Team · 15

Avraham Molcho
Founder · Board Member
Philip A. Serlin
Chief Executive Officer
Mali Zeevi
Chief Financial Officer
Ella Sorani
Chief Development Officer
Jael Birenberg
Vice President, Regulatory Affairs, Quality Assurance & Pharmacovigilance
Irit Gliko-Kabir
Vice President, Clinical Operations
Efrat Halbfinger
Vice President, Chemistry and Formulation
Bela Neiman
Vice President, Analytical Chemistry
Aharon Schwartz
Chairman
BJ Bormann
Board Member
Gal Cohen
Board Member
Rami Dar
Board Member
Rafael Hofstein
Board Member
Sandra Panem
Board Member
Shaoyu Yan
Board Member

Sectors & technology

Primary sector
Biotechnology
Target customers

Highlights

1 Patents

Tags

viral-diseasescancerinflammatory-diseasespharma-companiesdrug-discoverypharmaceuticalscancer-therapyimmunotherapyoncology
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)

External links

Websitebiolinerx.com
LinkedInlinkedin.com/company/112275
Facebookfacebook.com/BioLineRx-786986118113858
YouTubeyoutube.com/channel/UCjC1p4AbGeSzk1MjVaTEbAQ
Wikipediaen.wikipedia.org/wiki/BioLineRx
Wikidatawikidata.org/wiki/Q4914627

Identifiers & details

Legal nameBioLineRx Ltd.
Founded2003
Employees (exact)25
Market cap$13.1M
Status reasonPublic on TASE on Apr, 2007;Public on NASDAQ on Mar, 2014;
Wikidata QIDQ4914627

Acquisitions & public offerings

AcquiredDateAmount
Agalimmune2017-03$6.0M
TypeDateExchangeTickerAmount
IPO2007-02TASEBLRX$50.0M
ADR Listing2011-07NASDAQ Capital MarketBLRX
Public Offering2015-03NASDAQBLRX
Public Offering2017-04NASDAQBLRX$25.0M

Radar intelligence

Patents

EPO31

Publications (Crossref)

Works10

Web history (Wayback)

Domainbiolinerx.com

Wikidata

QIDQ4914627

Certificate / subdomain footprint

Subdomains9

Israeli Companies Registrar (רשם החברות / ICA)

Registrar # (ח.פ.)513398750
Statusפעילה
Corp typeישראלית חברה ציבורית
Incorporated2003-04-02
Purposeלעסוק בסוגי עיסוק שפורטו בתקנון
Liabilityמוגבלת
In violation (unfiled)no
Last annual report2005
Active charges / liens0
Registry events1 — charge (1)
Registered addressהמעיין 2 מודיעין-מכבים-רעות

Recent registry events

DateEvent
2025-11-06עדכון שעבוד